Viridian Therapeutics, Inc.\DE (VRDN) Invested Capital (2014 - 2025)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Invested Capital came in at $8.4 million in Q2 2025, up 184.58% year-on-year from $3.0 million in Q2 2024, and up 184.58% quarter-over-quarter from $3.0 million in Q2 2024.
Viridian Therapeutics, Inc.\DE (VRDN) Invested Capital (2014 - 2025) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Invested Capital history runs 3 years deep, the most recent figure standing at $8.4 million for Q2 2025.
- On a quarterly basis, Invested Capital rose 184.58% year-over-year to $8.4 million in Q2 2025; TTM through Mar 2026 was $8.4 million, a 184.58% increase from a year earlier, with the FY2014 full-year figure at $164000.0, changed N/A from the prior year.
- Invested Capital advanced to $8.4 million in Q2 2025 per VRDN's latest filing, from $3.0 million in the prior quarter.
- Across five years, Invested Capital topped out at $8.4 million in Q2 2025 and bottomed at $3.0 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | - |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - | 110.96 Mn |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn | 116.14 Mn |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | - |
| 10 | Viridian Therapeutics, Inc.\DE | 648.39 Mn | 648.39 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 8.44 Mn |
| Jun 30, 2024 | 2.96 Mn |
| Dec 31, 2014 | 164,000.00 |
| Sep 30, 2014 | 1.05 Mn |
| Jun 30, 2014 | 1.05 Mn |